Morgan Stanley Dia Medica Therapeutics Inc. Transaction History

Morgan Stanley

$1.27 Trillion
Q2 2024

A detailed history of Morgan Stanley transactions in Dia Medica Therapeutics Inc. stock. As of the latest transaction made, Morgan Stanley holds 86,200 shares of DMAC stock, worth $379,280. This represents 0.0% of its overall portfolio holdings.

Number of Shares

86,200

Previous 91,573 5.87%

Holding current value

$379,280

Previous $253,000 0.4%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Oct 17, 2024	SELL	$2.16 - $3.66 $11,605 - $19,665	-5,373 Reduced 5.87%	86,200 $254,000
Q2 2024 Aug 14, 2024	SELL	$2.16 - $3.66 $11,605 - $19,665	-5,373 Reduced 5.87%	86,200 $254,000
Q1 2024 Oct 17, 2024	BUY	$2.58 - $3.23 $13,862 - $17,354	5,373 Added 6.23%	91,573 $253,000
Q1 2024 Aug 16, 2024	SELL	$2.58 - $3.23 $75,908 - $95,033	-29,422 Reduced 24.32%	91,573 $253,000
Q1 2024 May 15, 2024	SELL	$2.58 - $3.23 $75,908 - $95,033	-29,422 Reduced 24.32%	91,573 $253,000
Q4 2023 Aug 16, 2024	BUY	$2.05 - $2.99 $71,329 - $104,037	34,795 Added 40.37%	120,995 $343,000
Q4 2023 Feb 13, 2024	BUY	$2.05 - $2.99 $55,749 - $81,313	27,195 Added 28.99%	120,995 $343,000
Q3 2023 Nov 15, 2023	BUY	$2.56 - $4.4 $93,952 - $161,480	36,700 Added 64.27%	93,800 $242,000
Q2 2023 Aug 14, 2023	SELL	$1.53 - $4.4 $134 - $387	-88 Reduced 0.15%	57,100 $246,000
Q1 2023 May 15, 2023	BUY	$1.32 - $1.89 $2,622 - $3,755	1,987 Added 3.6%	57,188 $87,000
Q4 2022 Feb 14, 2023	BUY	$1.13 - $1.62 $2,479 - $3,554	2,194 Added 4.14%	55,201 $87,000
Q3 2022 Nov 14, 2022	BUY	$1.2 - $2.07 $6,248 - $10,778	5,207 Added 10.89%	53,007 $66,000
Q2 2022 Oct 27, 2022	BUY	$1.86 - $2.62 $26,741 - $37,667	14,377 Added 43.02%	47,800 $96,000
Q2 2022 Aug 15, 2022	BUY	$1.86 - $2.62 $26,741 - $37,667	14,377 Added 43.02%	47,800 $96,000
Q1 2022 Oct 27, 2022	SELL	$2.29 - $3.88 $32,923 - $55,782	-14,377 Reduced 30.08%	33,423 $84,000
Q1 2022 May 13, 2022	BUY	$2.29 - $3.88 $21,807 - $36,949	9,523 Added 39.85%	33,423 $84,000
Q4 2021 Feb 14, 2022	BUY	$3.43 - $4.65 $42,875 - $58,125	12,500 Added 109.65%	23,900 $89,000
Q3 2021 Nov 15, 2021	BUY	$3.1 - $4.32 $35,340 - $49,248	11,400 New	11,400 $46,000

Others Institutions Holding DMAC

# of Institutions

Shares Held

3.87M

Call Options Held

1.3K

Put Options Held

View Full List

About DiaMedica Therapeutics Inc.

Ticker DMAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,443,100
Market Cap $116M
Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...

More about DMAC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account